HC Wainwright Has Negative Estimate for enGene Q2 Earnings

enGene Holdings Inc. (NASDAQ:ENGN) – HC Wainwright dropped their Q2 2025 earnings per share estimates for enGene in a note issued to investors on Tuesday, March 11th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.60) for the quarter, down from their prior estimate of ($0.44). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for enGene’s Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($1.93) EPS, FY2028 earnings at ($0.96) EPS and FY2029 earnings at ($0.15) EPS.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06.

Other equities research analysts have also issued research reports about the company. Piper Sandler assumed coverage on enGene in a research report on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price target on the stock. Morgan Stanley dropped their target price on enGene from $37.00 to $34.00 and set an “overweight” rating on the stock in a research report on Tuesday. Citizens Jmp raised enGene to a “strong-buy” rating in a research report on Monday, November 18th. Raymond James started coverage on enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price on the stock. Finally, UBS Group lowered enGene from a “buy” rating to a “neutral” rating and dropped their target price for the company from $34.00 to $7.00 in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, enGene presently has a consensus rating of “Buy” and a consensus price target of $25.22.

enGene Trading Up 2.7 %

NASDAQ ENGN opened at $5.29 on Thursday. The firm has a market cap of $269.67 million, a P/E ratio of -9.12 and a beta of -0.61. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The stock’s 50-day moving average is $6.59 and its 200-day moving average is $7.13. enGene has a one year low of $4.42 and a one year high of $18.40.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ENGN. Franklin Resources Inc. boosted its stake in shares of enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after acquiring an additional 389,918 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after acquiring an additional 619,100 shares during the period. Vontobel Holding Ltd. bought a new position in shares of enGene during the 4th quarter worth approximately $69,000. Wolverine Asset Management LLC bought a new position in shares of enGene during the 3rd quarter worth approximately $37,000. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of enGene by 15.7% during the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after acquiring an additional 2,080 shares during the period. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.